Published in Healthcare Mergers, Acquisitions and Ventures Week, April 17th, 2004
The decision finds all claims in the issued ACT nuclear-transfer patent to be unpatentable.
All motions filed by ACT were denied, including motions attacking the patentability of Geron's claims.
This proceeding is one of two interferences that have so far been declared by the Patent Office, at Geron's request, involving patents licensed to ACT. The patent...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.